Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Authors
Eisen, TMarais, R
Affolter, A
Lorigan, Paul C
Robert, C
Corrie, P
Ottensmeier, C
Chevreau, C
Chao, D
Nathan, P D
Jouary, T
Harries, M
Negrier, S
Montegriffo, E
Ahmad, T
Gibbens, I
James, M G
Strauss, U P
Prendergast, S
Gore, M E
Affiliation
Department of Oncology (R4), Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK. tgqe2@cam.ac.ukIssue Date
2011-07-26
Metadata
Show full item recordAbstract
The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I dose-escalation study and the activity of the combination was explored in an open-label phase II study.Citation
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. 2011, 105 (3):353-9 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/bjc.2011.257PubMed ID
21750549PubMed Central ID
PMC3172912Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2011.257
Scopus Count
Related articles
- Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
- Authors: McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E
- Issue date: 2008 May 1
- Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
- Authors: Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC
- Issue date: 2009
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
- Authors: Robert C, Dummer R, Gutzmer R, Lorigan P, Kim KB, Nyakas M, Arance A, Liszkay G, Schadendorf D, Cantarini M, Spencer S, Middleton MR
- Issue date: 2013 Jul
- Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
- Authors: Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P
- Issue date: 2009 Oct
- A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
- Authors: Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C
- Issue date: 2011 Dec 15